A substantial proportion of adults with hereditary angioedema (HAE) in the Netherlands have poorly controlled disease, significantly affecting their quality of life, a survey study reported. Findings also linked well-controlled HAE to lower medical costs and greater productivity, relative to patients without adequate disease control. “Additional [preventive treatment] strategies…
Astria Therapeutics intends to move directly into a pivotal trial to support STAR-0215’s regulatory approval for hereditary angioedema (HAE) if proof-of-concept results from the ongoing Phase 1b/2 trial are positive, the company has announced. Initial results from the trial, called ALPHA-STAR (NCT05695248), are expected in mid-2024. With…
A 60-year-old man developed sudden angioedema as a result of losartan, a medication commonly used to treat high blood pressure, a U.S. case study reported. Losartan, sold under the brand name Cozaar, is often used to manage cardiovascular diseases and high blood pressure. To date, only a few…
The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to NTLA-2002, an experimental gene-editing therapy that Intellia Therapeutics is developing to treat hereditary angioedema (HAE). RMAT designation is granted to therapies with the potential to treat, reverse, or cure serious or life-threatening…
Diagnosing and treating hereditary angioedema (HAE) can be challenging, but it is particularly difficult when patients live in rural areas of the U.S., a study based on a survey of allergy and immunology specialists reported. “Misdiagnosis of symptoms, access to a specialist, and affording medications remain…
Garadacimab, a preventive treatment candidate from CSL Behring, led to significant and clinically meaningful reductions in swelling attacks in patients with hereditary angioedema (HAE), according to published data from the Phase 3 VANGUARD clinical trial. The company expects to seek garadacimab’s approval from global health authorities later this…
The Canadian Agency for Drugs and Technologies in Health (CADTH) has recommended Orladeyo (berotralstat) be reimbursed by public drug plans when used for the routine prevention of hereditary angioedema (HAE) attacks in patients 12 years and older. “We are still in need of additional options to help people…
A 61-year-old woman in the U.S. was diagnosed with acquired angioedema and an underlying lymphoproliferative disorder after she sought treatment in an emergency department for sudden tongue swelling and difficulties in talking and swallowing, according to a case study. Lymphoproliferative disorders are characterized by the uncontrolled production of lymphocytes,…
The U.S. Food and Drug Administration (FDA) has given Intellia Therapeutics permission to open U.S. sites in its ongoing clinical trial of NTLA-2002, an investigational gene-editing therapy for hereditary angioedema (HAE). Specifics are not yet available on the number or location of U.S. sites for the global Phase…
People with hereditary angioedema (HAE) who took Orladeyo (berotralstat) for up to two years experienced no swelling attacks for most of the treatment duration, with fewer swelling attacks translating into a better quality of life. That’s according to results from APeX-S and APeX-2, two clinical studies that evaluated…
Get regular updates to your inbox.